Clinical Scenario

This protocol applies to patients with fibrous dysplasia experiencing bone pain that lacks neuropathic features — pain that is not characterised by burning or stabbing sensations. That clinical distinction matters because non-neuropathic bone pain follows a distinct management pathway.

After prior treatment failure

When the Previous Step Did Not Work

The preceding step used intravenous pamidronate or zoledronate for persistent moderate to severe bone pain. When that treatment fails to achieve the expected targets — improvement in bone pain VAS score and adequate pain relief — a structured next step is indicated. This protocol defines that step.

Treatment Approach (Summary — Partial)

At this stage, the approach involves switching to the alternative intravenous bisphosphonate: the agent not used in the prior line. Before doing so, non-bone causes of pain should be considered. The complete decision criteria, clinical thresholds, and full management sequence are available in the structured protocol.

Target: Improvement in bone pain VAS score

References

DOI: 10.1186/s13023-019-1102-9

If there is an inadequate clinical improvement, as measured by no or insufficient change in pain score, other non-bone causes of pain should be excluded before switching to the other parenteral bisphosphonate.
If there is still no improvement in pain, then do not continue with bisphosphonate therapy and review other causes of pain and consider other analgesic strategies.
If neuropathic features such as burning or stabbing pain are present, consider an atypical analgesic ladder, e.g. amitriptyline, gabapentin, pregabalin and duloxetine.
The aim of initial dosing is to establish whether bisphosphonates are effective in providing pain relief.

View source ↗

Bone Pain in Fibrous Dysplasia When Intravenous Bisphosphonate Therapy Has Not Achieved Adequate Pain Relief

Clinical Scenario

When the Previous Step Did Not Work

Treatment Approach (Summary — Partial)

References